|- candidate number||6889|
|- NTR Number||NTR2177|
|- ISRCTN||ISRCTN wordt niet meer aangevraagd.|
|- Date ISRCTN created|
|- date ISRCTN requested|
|- Date Registered NTR||16-jan-2010|
|- Secondary IDs||09/212 AENEAS|
|- Public Title||The AENEAS study: the Application of an Electronic Nose in the Early detection of ASpergillosis.|
|- Scientific Title||The AENEAS study: the Application of an Electronic Nose in the Early detection of ASpergillosis.|
|- ACRONYM||the AENEAS study|
|- Healt Condition(s) or Problem(s) studied||Invasive pulmonary aspergillosis|
|- Inclusion criteria||Patients that:|
1. Are 18 years of age or older;
2. Will undergo treatment for a hematological malignancy expected to result in grade 4 neutropenia (according to CTCAE 3.0, i.e. <0.5 x 109 neutrophils/L) of prolonged duration (i.e., more than 7 days), e.g. hematopoietic stem cell transplantation or induction/consolidation treatment for acute myeloid leukaemia;
3. Have given written informed consent.
If the neutropenic episode is part of a sequence of prolonged neutropenias, the informed consent will apply to all neutropenic episodes. The moment anti-mold treatment is started, the patient will go off-protocol after analysis of exhaled air using the eNose.
|- Exclusion criteria||1. A previously diagnosed invasive mycosis;|
2. The inability to perform the breathing manoeuvre needed for eNose-analysis of exhaled air.
|- mec approval received||yes|
|- multicenter trial||no|
|- Type||Single arm|
|- planned startdate ||1-okt-2010|
|- planned closingdate||1-okt-2012|
|- Target number of participants||90|
|- Interventions||Exhaled breath analysis using an electronic nose and gas chromatography-mass spectometry.|
|- Primary outcome||The accuracy with which an eNose can discriminate between patients with probable or proven invasive pulmonary aspergillosis and neutropenic controls with fever, as measured by the cross-validated values of the sensitivity, specificity and accuracy of the predictive algorithm. |
|- Secondary outcome||The accuracy in discriminating neutropenic controls with fever from healthy volunteers using the algorithm derived for the primary endpoint, as measured by the cross-validated values of the sensitivity, specificity and accuracy of the predictive algorithm.|
|- Trial web site||N/A|
|- CONTACT FOR PUBLIC QUERIES|| Koen Heer, de|
|- CONTACT for SCIENTIFIC QUERIES|| Koen Heer, de|
|- Sponsor/Initiator ||Academic Medical Center (AMC), Amsterdam|
(Source(s) of Monetary or Material Support)
|Academic Medical Center (AMC), Amsterdam|
|- Brief summary||Introduction|
There is a need for new diagnostic methods to facilitate earlier diagnosis and treatment of invasive pulmonary mycosis (IPM) during prolonged chemotherapy-induced neutropenia (PCIN). Exhaled breath analysis could fulfill this need.
Before studying serial samples during neutropenia, we will first establish the accuracy of exhaled breath analysis to discriminate patients with invasive pulmonary aspergillosis (IPA), the most frequent cause of IPM, from neutropenic controls with fever.
Single center study with a prospective cohort design. Patients will be sampled once.
Patients that will undergo treatment for a hematological malignancy expected to result in grade 4 neutropenia for more than 7 days (PCIN).
Cases: Patients with probable or proven IPA and a positive galactomannan assay on bronchoalveolar lavage (BAL).
Controls: Patients with fever but no possible, probable or proven IPM and no positive galactomannan assay performed on serum and BAL.
Exhaled breath analysis using an electronic nose (eNose) and gas chromatography-mass spectrometry
(GC-MS). GC-MS will be used to unravel the molecular mechanisms by which the eNose detects aspergillosis.
The accuracy with which an eNose can discriminate between cases and controls as measured by the
cross-validated accuracy of the predictive algorithm. Raw data are analysed by discriminant analysis on principal component reduction after which the results will be validated using the “leave-one-out” method.
Our aim is to include 125 neutropenic episodes in 80 patients resulting in 10 cases and 10 controls.
Accrual will take an estimated 18 months, data analysis and writing the publication 6 months. During the accrual we will in parallel perform additional research in vitro and in CF patients for our GC-MS analyses.
A limited economic evaluation will be performed by modelling the diagnosis of IPA using a decision tree. The cost and accuracy of various combinations of diagnostic procedures will be determined. We will establish whether the addition of the eNose to the non-invasive work-up of suspected IPA obviates BAL without a loss in health.
|- Main changes (audit trail)|
|- RECORD||16-jan-2010 - 7-feb-2010|